PERRIGO COMPANY PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.8 USD | +2.87% |
|
+1.58% | -4.29% |
| Apr. 08 | Piper Sandler Raises Perrigo's Price Target to $39 From $35, Maintains Overweight Rating | MT |
| Apr. 04 | CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors | RE |
Financials (USD)
| Sales 2024 * | 4.66B | Sales 2025 * | 4.86B | Capitalization | 4.06B |
|---|---|---|---|---|---|
| Net income 2024 * | -51M | Net income 2025 * | 101M | EV / Sales 2024 * | 1.55 x |
| Net Debt 2024 * | 3.16B | Net Debt 2025 * | 2.91B | EV / Sales 2025 * | 1.43 x |
| P/E ratio 2024 * |
-80.9
x | P/E ratio 2025 * |
63.7
x | Employees | 9,140 |
| Yield 2024 * |
3.68% | Yield 2025 * |
3.92% | Free-Float | 99.69% |
More Fundamentals
* Assessed data
More news
Latest transcript on Perrigo Company plc
More recommendations
More press releases
More news
| 1 day | -0.33% | ||
| 1 week | -4.28% | ||
| Current month | -6.99% | ||
| 1 month | -0.23% | ||
| 3 months | -8.66% | ||
| 6 months | -0.47% | ||
| Current year | -6.96% |
1 week
29.79
30.78
1 month
29.7932.46
Current year
25.7734.60
1 year
25.7740.28
3 years
25.7750.90
5 years
25.7763.86
10 years
25.77215.73
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 23-06-29 | |
Eduardo Bezerra
DFI | Director of Finance/CFO | 49 | 22-05-15 |
Alison Ives
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Orlando Ashford
CHM | Chairman | 55 | 20-12-14 |
Jeffrey Kindler
BRD | Director/Board Member | 68 | 17-02-05 |
Bradley Alford
BRD | Director/Board Member | 67 | 17-02-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 18.63% | 13 M€ | -.--% | ||
| 15.31% | 215 M€ | +12.86% | - | |
| 0.66% | 8 M€ | +5.48% | - | |
| 0.46% | 2 M€ | +5.19% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 30.8 | +2.87% | 1 168 219 |
| 24-04-18 | 29.94 | -0.33% | 971,548 |
| 24-04-17 | 30.04 | +0.27% | 777,079 |
| 24-04-16 | 29.96 | -0.56% | 1,450,950 |
| 24-04-15 | 30.13 | -0.63% | 1,663,149 |
Delayed Quote Nyse, April 18, 2024 at 04:00 pm EDT
More quotes
Perrigo Company plc is an Ireland-based provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. The Company's segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises its consumer self-care business (OTC, infant formula, and oral care categories, and contract manufacturing) in the United States and Canada, including the HRA Pharma self-care business (Women's Health and Skin-Care categories) in the United States and Canada. The CSCI segment comprises its consumer self-care business in Europe and Australia, which are primarily branded, its store brand business in the United Kingdom and parts of Europe and Asia and includes the HRA Pharma self-care business (Women's Health, Skin-Care and Rare-Disease categories) in Europe. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, Nutrition and others.
Sector
Pharmaceuticals
Calendar
2024-05-02
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
29.94
USD
Average target price
39.75
USD
Spread / Average Target
+32.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.96% | 4.06B | |
| +27.97% | 672B | |
| +23.68% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.02% | 211B | |
| -0.48% | 203B | |
| -10.22% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- PRGO Stock
